E7

Dry (Atrophic) Macular Degeneration Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 17, 2024
Health, Clinical Trials, E7, Clinical trial, Macular degeneration, Atrophy, G7, Trial, Ophthalmology, Pharmaceutical industry

The "Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report provides an overview of Dry (Atrophic) Macular Degeneration Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Bronchiectasis Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
onsdag, maj 15, 2024
Health, Pharmaceutical, E7, Clinical trial, G7, Trial, Pharmaceutical industry

The "Bronchiectasis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bronchiectasis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report provides top line data relating to the clinical trials on Bronchiectasis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Bronchiectasis to Respiratory Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Bronchiectasis to Respiratory Clinical Trials

Hyperglycemia Global Clinical Trials Review 2024: Phase, Trial Status, End Points Status, Sponsor Type, Region, Country (G7 & E7) - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 10, 2024
Health, Pharmaceutical, Clinical, E7, Clinical trial, News, G7, Trial, Pharmaceutical industry

The "Hyperglycemia - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyperglycemia - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides top line data relating to the clinical trials on Hyperglycemia.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database.

Arthralgia (Joint Pain) Global Clinical Trials Review 2024 Featuring Novartis, J&J, Reckitt Benckiser, Grunenthal, IBSA Institut Biochimique, GSK, Sandoz, Atoll, ESM Technologies, Pfizer - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 10, 2024
Health, Clinical Trials, E7, Trial, News, Clinical trial, Central nervous system, Clinical, G7

The "Arthralgia (Joint Pain) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Arthralgia (Joint Pain) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides an overview of Arthralgia (Joint Pain) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Arthralgia (Joint Pain).
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review 2024: Phase, Trial Status, End Points Status, Sponsor Type and Region, Country (G7 & E7) - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 10, 2024
Pharmaceutical, Health, Clinical Trials, E7, Trial, News, Hurler syndrome, Clinical trial, Mucopolysaccharidosis, Clinical, G7, Pharmaceutical industry

The "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) .
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2024 Featuring Pfizer, Novartis, Sanofi, Regeneron, LEO, Eli Lilly and Co, AbbVie, GSK, Innovaderm Research, and Johnson & Johnson - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 10, 2024
Health, General Health, E7, Trial, Dermatitis, News, Clinical trial, Dermatology, Atopic dermatitis, Clinical, G7, Pharmaceutical industry

The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides top line data relating to the clinical trials on Atopic Dermatitis (Atopic Eczema).
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
onsdag, mars 27, 2024
MSD, Research, Conference call, Conference, Head, AstraZeneca, E7, Patient, Merck & Co., Tumor microenvironment, Merck, News, R&I, Cancer, Virus, MD, E6, Lung cancer, AACR, NEC, European Journal, HPV16, Euronext Paris, De novo, Immune system, ASCO, Safety, Poster, Potyvirus, Pharmaceutical industry

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Cabot Corporation Launches New PROPEL® E8 Engineered Reinforcing Carbon Black for Tire Tread Applications

Retrieved on: 
måndag, mars 18, 2024
Environment, Alternative Vehicles, Fuels, EV, Electric Vehicles, Aftermarket, Automotive, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Sustainability, EVS, E7, Corporation, ASTM, PROPEL, E6, ICE, Carbon, Torque, Cabot Corporation, Tire manufacturing

Cabot Corporation (NYSE: CBT) today announced the global launch of its new PROPEL® E8 engineered reinforcing carbon black designed to provide superior tread durability at low rolling resistance for high-performance tire tread applications.

Key Points: 
  • Cabot Corporation (NYSE: CBT) today announced the global launch of its new PROPEL® E8 engineered reinforcing carbon black designed to provide superior tread durability at low rolling resistance for high-performance tire tread applications.
  • The PROPEL E8 grade complements Cabot’s existing solutions within the PROPEL E series, which are also suitable for use in high-performance tires.
  • The PROPEL E8 solution enables better rolling resistance when compared to ASTM N200 and N100 carbon black grades.
  • For more information about Cabot’s comprehensive suite of products for EV tires and high-performance tire tread applications, visit cabotcorp.com/tire .

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Retrieved on: 
torsdag, januari 25, 2024
Tumor microenvironment, Death, Patient, Therapy, Neoplasm, AMP, Cancer, E7, Peptide, Immunotherapy, Risk, Recurrence, Lymph, Cancer Immunology Research, Doctor of Philosophy, NY-ESO-1, Research, Vaccine

These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.

Key Points: 
  • These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.
  • “Optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics.
  • “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication.
  • AMP immunotherapy led to enhanced lymph node delivery and correlated with pro-inflammatory lymph node transcriptional reprogramming and increased antigen-presenting cell maturation, resulting in TCR-T cell expansion and functional enhancement.

Down Syndrome Clinical Trials 2023: Comprehensive Global Analysis Report, Highlighting Regional Trends, Phases, and Sponsor Types - ResearchAndMarkets.com

Retrieved on: 
fredag, december 22, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Clinical trial, Trial, News, G7, E7, Down syndrome, Pharma, Clinical, Pharmaceutical industry

The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.

Key Points: 
  • The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Down Syndrome.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.